{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T07:15:56Z","timestamp":1772694956901,"version":"3.50.1"},"reference-count":101,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.lpm.2022.104109","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T01:54:40Z","timestamp":1641866080000},"page":"104109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cutaneous B-cell lymphomas: Update on diagnosis, risk-stratification, and management"],"prefix":"10.1016","volume":"51","author":[{"given":"Paolo","family":"Fava","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7126-5506","authenticated-orcid":false,"given":"Gabriele","family":"Roccuzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Alberti-Violetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vieri","family":"Grandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1025-7171","authenticated-orcid":false,"given":"Alessandro","family":"Pileri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Pimpinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Berti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.lpm.2022.104109_bib0001","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.lpm.2022.104109_bib0002","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/jid.2013.393","article-title":"Changing incidence trends of cutaneous B-cell lymphoma","volume":"134","author":"Korgavkar","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"21","key":"10.1016\/j.lpm.2022.104109_bib0003","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2022.104109_bib0004","series-title":"Skin lymphoma: the illustrated guide","author":"Cerroni","year":"2020"},{"issue":"2","key":"10.1016\/j.lpm.2022.104109_bib0005","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/archdermatol.2009.340","article-title":"Anetodermic primary cutaneous B-cell lymphoma: a unique clinicopathological presentation of lymphoma possibly associated with antiphospholipid antibodies","volume":"146","author":"Hodak","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.lpm.2022.104109_bib0006","unstructured":"SH S, E C, NL H, et\u00a0al. WHO Classification of tumours of haematopoietic and lymphoid tissues. Accessed November 22, 2020. https:\/\/publications.iarc.fr\/Book-And-Report-Series\/Who-Classification-Of-Tumours\/WHO-Classification-Of-Tumours-Of-Haematopoietic-And-Lymphoid-Tissues-2017"},{"issue":"8","key":"10.1016\/j.lpm.2022.104109_bib0007","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3324\/haematol.2009.005983","article-title":"Chronic inflammatory disease, lymphoid tissue neogenesis and extranodal marginal zone B-cell lymphomas","volume":"94","author":"Bende","year":"2009","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.lpm.2022.104109_bib0008","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1182\/blood-2005-09-3679","article-title":"Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation","volume":"107","author":"Suarez","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.lpm.2022.104109_bib0009","doi-asserted-by":"crossref","first-page":"E123","DOI":"10.1002\/ajh.26103","article-title":"Survival of patients with marginal zone lymphoma in the United States: A population-based cohort study (2000 to 2017)","volume":"96","author":"Vaughn","year":"2021","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.lpm.2022.104109_bib0010","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/DAD.0b013e31818118f7","article-title":"Evaluation of B-cell clonality using the BIOMED-2 PCR method effectively distinguishes cutaneous B-cell lymphoma from benign lymphoid infiltrates","volume":"30","author":"Morales","year":"2008","journal-title":"Am J Dermatopathol"},{"issue":"12","key":"10.1016\/j.lpm.2022.104109_bib0011","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1097\/PAS.0b013e3181f72835","article-title":"Cutaneous marginal zone lymphomas have distinctive features and include 2 subsets","volume":"34","author":"Edinger","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"10.1016\/j.lpm.2022.104109_bib0012","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/00000478-200308000-00003","article-title":"Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathologic study of 24 asian cases","volume":"27","author":"Li","year":"2003","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"10.1016\/j.lpm.2022.104109_bib0013","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.humpath.2006.02.012","article-title":"Aberrant nuclear BCL10 expression and lack of t(11;18)(q21;q21) in primary cutaneous marginal zone B-cell lymphoma","volume":"37","author":"Gallardo","year":"2006","journal-title":"Hum Pathol"},{"issue":"6","key":"10.1016\/j.lpm.2022.104109_bib0014","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1182\/blood-2002-09-2963","article-title":"T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma","volume":"101","author":"Streubel","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.lpm.2022.104109_bib0015","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/DAD.0b013e31804795a6","article-title":"Primary cutaneous marginal zone B-cell lymphoma may exhibit both the t(14;18)(q32;q21) IGH\/BCL2 and the t(14;18)(q32;q21) IGH\/MALT1 translocation: an indicator for clonal transformation towards higher-grade B-cell lymphoma?","volume":"29","author":"Palmedo","year":"2007","journal-title":"Am J Dermatopathol"},{"issue":"4","key":"10.1016\/j.lpm.2022.104109_bib0016","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/sj.leu.2403644","article-title":"T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma","volume":"19","author":"Streubel","year":"2005","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.lpm.2022.104109_bib0017","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1182\/blood-2008-01-132415","article-title":"The majority of cutaneous marginal zone B-cell lymphomas expresses class-switched immunoglobulins and develops in a T-helper type 2 inflammatory environment","volume":"112","author":"van Maldegem","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.lpm.2022.104109_bib0018","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jid.2018.02.015","article-title":"Panel Sequencing Shows Recurrent Genetic FAS Alterations in Primary Cutaneous Marginal Zone Lymphoma","volume":"138","author":"Maurus","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.lpm.2022.104109_bib0019","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1046\/j.1523-1747.2002.01785.x","article-title":"Inactivation of tumor suppressor genes p15(INK4b) and p16(INK4a) in primary cutaneous B cell lymphoma","volume":"118","author":"Child","year":"2002","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.lpm.2022.104109_bib0020","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/jid.2008.243","article-title":"Primary cutaneous marginal zone B-cell lymphomas are targeted by aberrant somatic hypermutation","volume":"129","author":"Deutsch","year":"2009","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.lpm.2022.104109_bib0021","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1365-2133.2009.09576.x","article-title":"Primary cutaneous B-cell lymphoma is associated with somatically hypermutated immunoglobulin variable genes and frequent use of VH1-69 and VH4-59 segments","volume":"162","author":"Perez","year":"2010","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.lpm.2022.104109_bib0022","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1182\/blood.V99.3.800","article-title":"Primary cutaneous lymphomas: applicability of current classification schemes (European Organization for Research and Treatment of Cancer, World Health Organization) based on clinicopathologic features observed in a large group of patients","volume":"99","author":"Fink-Puches","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.lpm.2022.104109_bib0023","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/j.1365-2133.2006.07264.x","article-title":"Relative frequency and survival of patients with primary cutaneous lymphomas: data from a single-centre study of 203 patients","volume":"154","author":"Bouaziz","year":"2006","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.lpm.2022.104109_bib0024","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.2005.03.6285","article-title":"Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas","volume":"24","author":"Zinzani","year":"2006","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.lpm.2022.104109_bib0025","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jaad.2013.04.047","article-title":"Primary cutaneous marginal zone B-cell lymphoma: response to treatment and disease-free survival in a series of 137 patients","volume":"69","author":"Servitje","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.lpm.2022.104109_bib0026","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/bjd.15071","article-title":"Primary cutaneous B-cell lymphoma: systemic spread is rare while cutaneous relapses and secondary malignancies are frequent","volume":"177","author":"Chan","year":"2017","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.lpm.2022.104109_bib0027","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00277-010-1083-1","article-title":"CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11)","volume":"90","author":"Mian","year":"2011","journal-title":"Ann Hematol"},{"issue":"Suppl 4","key":"10.1016\/j.lpm.2022.104109_bib0028","doi-asserted-by":"crossref","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","article-title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Willemze","year":"2018","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.lpm.2022.104109_bib0029","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/blood-2008-04-152850","article-title":"European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas","volume":"112","author":"Senff","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.lpm.2022.104109_bib0030","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0046-8177(00)80233-6","article-title":"Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin","volume":"31","author":"Roggero","year":"2000","journal-title":"Hum Pathol"},{"issue":"2 Pt 2","key":"10.1016\/j.lpm.2022.104109_bib0031","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0190-9622(97)80405-7","article-title":"Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a","volume":"36","author":"K\u00fctting","year":"1997","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.lpm.2022.104109_bib0032","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/j.1365-2133.2003.05649.x","article-title":"Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance","volume":"149","author":"Hoefnagel","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.lpm.2022.104109_bib0033","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3389\/fonc.2020.00662","article-title":"BCL-2 Expression in primary cutaneous follicle center B-Cell lymphoma and its prognostic role","volume":"10","author":"Pileri","year":"2020","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.lpm.2022.104109_bib0034","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/cup.13399","article-title":"Primary cutaneous vs secondary cutaneous follicular lymphomas: A comparative study focused on BCL2, CD10, and t(14;18) expression","volume":"46","author":"Servitje","year":"2019","journal-title":"J Cutan Pathol"},{"issue":"1","key":"10.1016\/j.lpm.2022.104109_bib0035","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/PAS.0000000000000567","article-title":"Primary cutaneous follicle center lymphomas expressing BCL2 protein frequently harbor BCL2 gene break and may present 1p36 deletion: a study of 20 cases","volume":"40","author":"Szablewski","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.lpm.2022.104109_bib0036","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/01.pas.0000146015.22624.c7","article-title":"Clinicopathologic, immunophenotypic, and molecular cytogenetic fluorescence in situ hybridization analysis of primary and secondary cutaneous follicular lymphomas","volume":"29","author":"Kim","year":"2005","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"10.1016\/j.lpm.2022.104109_bib0037","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/cam4.865","article-title":"Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers","volume":"5","author":"Lucioni","year":"2016","journal-title":"Cancer Med"},{"issue":"Suppl 1","key":"10.1016\/j.lpm.2022.104109_bib0038","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41379-019-0385-7","article-title":"Navigating the cutaneous B-cell lymphomas: avoiding the rocky shoals","volume":"33","author":"Jaffe","year":"2020","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.lpm.2022.104109_bib0039","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/00000478-200106000-00004","article-title":"Cutaneous b-cell lymphomas of follicular and marginal zone types: use of Bcl-6, CD10, Bcl-2, and CD21 in differential diagnosis and classification","volume":"25","author":"de Leval","year":"2001","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"10.1016\/j.lpm.2022.104109_bib0040","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/jamadermatol.2014.821","article-title":"High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type","volume":"150","author":"Pham-Ledard","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.lpm.2022.104109_bib0041","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jaad.2014.01.862","article-title":"Chromosomal anomalies in primary cutaneous follicle center cell lymphoma do not portend a poor prognosis","volume":"70","author":"Abdul-Wahab","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.lpm.2022.104109_bib0042","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jaad.2010.06.059","article-title":"Clinicopathologic features of early lesions of primary cutaneous follicle center lymphoma, diffuse type: implications for early diagnosis and treatment","volume":"65","author":"Gulia","year":"2011","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.lpm.2022.104109_bib0043","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/blood-2005-03-1175","article-title":"Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients","volume":"106","author":"Kodama","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.lpm.2022.104109_bib0044","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2006-10-054601","volume":"110","author":"Kim","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.lpm.2022.104109_bib0045","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ajh.23863","article-title":"Cutaneous B-cell lymphomas: 2015 update on diagnosis, risk-stratification, and management","volume":"90","author":"Wilcox","year":"2015","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.lpm.2022.104109_bib0046","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.2005.03.6285","article-title":"Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas","volume":"24","author":"Zinzani","year":"2006","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.lpm.2022.104109_bib0047","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ijrobp.2013.07.019","article-title":"Treatment and outcomes in patients with primary cutaneous B-cell lymphoma: the BC Cancer Agency experience","volume":"87","author":"Hamilton","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.lpm.2022.104109_bib0048","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3389\/fonc.2020.00651","article-title":"Primary cutaneous B-cell lymphomas: an update","volume":"10","author":"Vitiello","year":"2020","journal-title":"Front Oncol"},{"issue":"3 Pt 1","key":"10.1016\/j.lpm.2022.104109_bib0049","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0190-9622(87)70068-1","article-title":"Primary cutaneous large cell lymphomas of follicular center cell origin. A clinical follow-up study of nineteen patients","volume":"16","author":"Willemze","year":"1987","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.lpm.2022.104109_bib0050","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/archderm.1996.03890350042008","article-title":"Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group","volume":"132","author":"Vermeer","year":"1996","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.lpm.2022.104109_bib0051","first-page":"354","article-title":"EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer","volume":"90","author":"Willemze","year":"1997","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.lpm.2022.104109_bib0052","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.lpm.2022.104109_bib0053","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.lpm.2022.104109_bib0054","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1001\/archderm.143.9.1144","article-title":"Primary cutaneous diffuse large B-cell lymphoma, Leg type: clinicopathologic features and prognostic analysis in 60 cases","volume":"143","author":"Grange","year":"2007","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.lpm.2022.104109_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2013.06.011","article-title":"Primary cutaneous B-cell lymphomas: part I. Clinical features, diagnosis, and classification","volume":"69","author":"Su\u00e1rez","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.lpm.2022.104109_bib0056","doi-asserted-by":"crossref","first-page":"466","DOI":"10.23736\/S0392-0488.17.05670-X","article-title":"Primary cutaneous B-cell lymphoma: narrative review of the literature","volume":"154","author":"Grandi","year":"2019","journal-title":"G Ital Dermatol Venereol"},{"issue":"7","key":"10.1016\/j.lpm.2022.104109_bib0057","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/PAS.0b013e3181e5060a","article-title":"IgM expression on paraffin sections distinguishes primary cutaneous large B-cell lymphoma, leg type from primary cutaneous follicle center lymphoma","volume":"34","author":"Koens","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.lpm.2022.104109_bib0058","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/jid.2013.265","article-title":"Nuclear factor-\u03baB pathway-activating gene aberrancies in primary cutaneous large B-cell lymphoma, leg type","volume":"134","author":"Koens","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"8","key":"10.1016\/j.lpm.2022.104109_bib0059","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.jid.2016.04.018","article-title":"MYD88 Somatic mutation is a diagnostic criterion in primary cutaneous large B-Cell lymphoma","volume":"136","author":"Menguy","year":"2016","journal-title":"J Invest Dermatol"},{"issue":"5","key":"10.1016\/j.lpm.2022.104109_bib0060","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/jid.2008.357","article-title":"Fine-mapping chromosomal loss at 9p21: correlation with prognosis in primary cutaneous diffuse large B-cell lymphoma, leg type","volume":"129","author":"Senff","year":"2009","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.lpm.2022.104109_bib0061","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jdermsci.2017.07.008","article-title":"Molecular analysis of immunoglobulin variable genes supports a germinal center experienced normal counterpart in primary cutaneous diffuse large B-cell lymphoma, leg-type","volume":"88","author":"Pham-Ledard","year":"2017","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.lpm.2022.104109_bib0062","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25970","article-title":"Cutaneous B-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management","author":"Hristov","year":"2020","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.lpm.2022.104109_bib0063","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00277-013-1787-0","article-title":"Lenalidomide monotherapy in relapsed primary cutaneous diffuse large B cell lymphoma-leg type","volume":"93","author":"Savini","year":"2014","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.lpm.2022.104109_bib0064","doi-asserted-by":"crossref","first-page":"6067","DOI":"10.4081\/rt.2015.6067","article-title":"Excellent outcome of immunomodulation or Bruton's tyrosine kinase inhibition in highly refractory primary cutaneous diffuse large B-cell lymphoma, Leg type","volume":"7","author":"Gupta","year":"2015","journal-title":"Rare Tumors"},{"issue":"9","key":"10.1016\/j.lpm.2022.104109_bib0065","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jid.2018.03.1516","article-title":"A single-arm Phase II trial of lenalidomide in relapsing or refractory primary cutaneous large B-cell lymphoma, Leg type","volume":"138","author":"Beylot-Barry","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.lpm.2022.104109_bib0066","series-title":"WHO Classification of tumors of haematopoietic and lymphoid tissues","first-page":"317","article-title":"Intravascular large B-cell lymphoma","author":"Nakamura","year":"2017"},{"key":"10.1016\/j.lpm.2022.104109_bib0067","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJM198604103141502","article-title":"Further evidence that malignant angioendotheliomatosis is an angiotropic large-cell lymphoma","volume":"314","author":"Sheibani","year":"1986","journal-title":"New Engl J Med"},{"issue":"21","key":"10.1016\/j.lpm.2022.104109_bib0068","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1200\/JCO.2006.08.2313","article-title":"Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting","volume":"25","author":"Ponzoni","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.lpm.2022.104109_bib0069","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/PAS.0b013e31815d29c9","article-title":"Intravascular large T-cell or NK-cell lymphoma: a rare variant of intravascular large cell lymphoma with frequent cytotoxic phenotype and association with Epstein-Barr virus infection","volume":"32","author":"Cerroni","year":"2008","journal-title":"Am J Surg Pathol"},{"issue":"15","key":"10.1016\/j.lpm.2022.104109_bib0070","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1182\/blood-2017-04-737445","article-title":"Intravascular large B-cell lymphoma: a chameleon with multiple faces and many masks","volume":"132","author":"Ponzoni","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.lpm.2022.104109_bib0071","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0046-8177(00)80223-3","article-title":"Lack of CD 29 (beta1 integrin) and CD 54 (ICAM-1) adhesion molecules in intravascular lymphomatosis","volume":"31","author":"Ponzoni","year":"2000","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1016\/j.lpm.2022.104109_bib0072","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1684\/ejd.2012.1639","article-title":"Decreased expression of homeostatic chemokine receptors in intravascular large B-cell lymphoma","volume":"22","author":"Kasuya","year":"2012","journal-title":"Eur J Dermatol"},{"issue":"7","key":"10.1016\/j.lpm.2022.104109_bib0073","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/leu.2016.67","article-title":"Development and analysis of patient-derived xenograft mouse models in intravascular large B-cell lymphoma","volume":"30","author":"Shimada","year":"2016","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.lpm.2022.104109_bib0074","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/hon.776","article-title":"Intravascular lymphoma: a neoplasm of \u2018homeless\u2019 lymphocytes?","volume":"24","author":"Ponzoni","year":"2006","journal-title":"Hematol Oncol"},{"issue":"10","key":"10.1016\/j.lpm.2022.104109_bib0075","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1002\/1097-0142(19930515)71:10<3156::AID-CNCR2820711043>3.0.CO;2-O","article-title":"Intravascular lymphomatosis a systemic disease with neurologic manifestations","volume":"71","author":"Glass","year":"1993","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.lpm.2022.104109_bib0076","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2141.2004.05177.x","article-title":"Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the \u2018cutaneous variant\u20191","volume":"127","author":"Ferreri","year":"2004","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.lpm.2022.104109_bib0077","first-page":"826","article-title":"An Asian variant of intravascular large B-cell lymphoma: clinical, pathological and cytogenetic approaches to diffuse large B-cell lymphoma associated with haemophagocytic syndrome","volume":"111","author":"Murase","year":"2000","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.lpm.2022.104109_bib0078","first-page":"641","article-title":"Intravascular lymphoma occurring in patients with other non-Hodgkin lymphomas","volume":"8","author":"Ponzoni","year":"2010","journal-title":"Clin Adv Hematol Oncol"},{"issue":"11","key":"10.1016\/j.lpm.2022.104109_bib0079","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/modpathol.3880450","article-title":"Angiotropic lymphoma: an immunophenotypically and clinically heterogeneous lymphoma","volume":"14","author":"Yegappan","year":"2001","journal-title":"Mod Pathol"},{"issue":"10","key":"10.1016\/j.lpm.2022.104109_bib0080","first-page":"983","article-title":"Intravascular large B-cell lymphoma: the CD5 antigen is expressed by a subset of cases","volume":"11","author":"Khalidi","year":"1998","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.lpm.2022.104109_bib0081","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/cup.13446","article-title":"CD30 expression in a case of intravascular large B-cell lymphoma, cutaneous variant","volume":"46","author":"Provasi","year":"2019","journal-title":"J Cutan Pathol"},{"issue":"2","key":"10.1016\/j.lpm.2022.104109_bib0082","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1182\/blood-2006-01-021253","article-title":"Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5","volume":"109","author":"Murase","year":"2007","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.lpm.2022.104109_bib0083","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1182\/blood-2017-12-822817","article-title":"High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma","volume":"131","author":"Schrader","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.lpm.2022.104109_bib0084","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/annonc\/mdh274","article-title":"Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma","volume":"15","author":"Ferreri","year":"2004","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.lpm.2022.104109_bib0085","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/bmt.2016.339","article-title":"Autologous hematopoietic stem cell transplantation for intravascular large B-cell lymphoma: the European Society for Blood and Marrow Transplantation experience","volume":"52","author":"Meissner","year":"2017","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.lpm.2022.104109_bib0086","series-title":"WHO Classification of tumours of haematopoietic and lymphoid tissue","first-page":"304","article-title":"EBV-positive diffuse large B-cell lymphoma, not otherwise specified (NOS)","author":"Nakamura","year":"2017"},{"issue":"3","key":"10.1016\/j.lpm.2022.104109_bib0087","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/10428190902725813","article-title":"Epstein-Barr virus positive diffuse large B-cell lymphoma of the elderly","volume":"50","author":"Wong","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.lpm.2022.104109_bib0088","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2013-03-489708","article-title":"EBV-positive diffuse large B-cell lymphoma of the elderly","volume":"122","author":"Ok","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.lpm.2022.104109_bib0089","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1002\/ccr3.3239","article-title":"Multiple cutaneous ulcers revealing a primary cutaneous Epstein-Barr virus-positive diffuse large B-cell lymphoma","volume":"8","author":"Tedbirt","year":"2020","journal-title":"Clin Case Rep"},{"issue":"5","key":"10.1016\/j.lpm.2022.104109_bib0090","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.humpath.2008.10.007","article-title":"Epstein-Barr virus-positive B-cell lymphoma of the elderly at a United States tertiary medical center: an uncommon aggressive lymphoma with a nongerminal center B-cell phenotype","volume":"40","author":"Gibson","year":"2009","journal-title":"Hum Pathol"},{"key":"10.1016\/j.lpm.2022.104109_bib0091","series-title":"Skin lymphoma, the illustrated guide","first-page":"326","article-title":"Other cutaneous B-cell lymphomas","author":"Cerroni","year":"2020"},{"issue":"6","key":"10.1016\/j.lpm.2022.104109_bib0092","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1182\/blood.V99.6.2009","article-title":"Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy","volume":"99","author":"Rossig","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2022.104109_bib0093","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/509296","article-title":"Advances in virus-directed therapeutics against epstein-barr virus-associated malignancies","volume":"2012","author":"Ghosh","year":"2012","journal-title":"Adv Virol"},{"issue":"18","key":"10.1016\/j.lpm.2022.104109_bib0094","doi-asserted-by":"crossref","first-page":"10029","DOI":"10.1128\/JVI.02241-06","article-title":"Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells","volume":"81","author":"Zou","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.lpm.2022.104109_bib0095","series-title":"WHO Classification of skin tumours","author":"Elder","year":"2018"},{"key":"10.1016\/j.lpm.2022.104109_bib0096","series-title":"The illustrated guide","first-page":"310","article-title":"Cutaneous diffuse large B-cell lymphoma, leg type","author":"Cerroni","year":"2020"},{"issue":"10","key":"10.1016\/j.lpm.2022.104109_bib0097","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/cam4.865","article-title":"Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers","volume":"5","author":"Lucioni","year":"2016","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.lpm.2022.104109_bib0098","first-page":"275","article-title":"Primary cutaneous diffuse large B-cell lymphoma, NOS and leg type: clinical, morphologic and prognostic differences","volume":"17","author":"Felcht","year":"2019","journal-title":"JDDG"},{"key":"10.1016\/j.lpm.2022.104109_bib0099","series-title":"WHO Classification of tumour of haematopoietic and lymphoid tussues","first-page":"298","article-title":"T cell\/histiocyte-rich B-cell lymphoma","author":"Ott","year":"2017"},{"key":"10.1016\/j.lpm.2022.104109_bib0100","unstructured":"Venizelos ID, Tatsiou ZA, Mandala E. Primary cutaneous T-cell-rich B-cell lymphoma: a case report and literature review. 2008;17(4):5."},{"issue":"3","key":"10.1016\/j.lpm.2022.104109_bib0101","first-page":"225","article-title":"Cutaneous T-cell\/histiocyte-rich B-cell lymphoma: a case report and review of the literature","volume":"222","author":"Vezzoli","year":"2011","journal-title":"DRM"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498222000021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498222000021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:07:30Z","timestamp":1760105250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498222000021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":101,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0755498222000021"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2022.104109","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous B-cell lymphomas: Update on diagnosis, risk-stratification, and management","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2022.104109","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104109"}}